We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ChemoCentryx Inc (CCXI) USD0.001

Sell:$35.86 Buy:$36.01 Change: $1.00 (2.71%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$35.86
Buy:$36.01
Change: $1.00 (2.71%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$35.86
Buy:$36.01
Change: $1.00 (2.71%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ChemoCentryx, Inc. is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.

Contact details

Address:
835 INDUSTRIAL ROAD, SUITE 600
SAN CARLOS
94070
United States
Telephone:
+1 (650) 2102900
Website:
www.chemocentryx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CCXI
ISIN:
US16383L1061
Market cap:
$2.54 billion
Shares in issue:
70.03 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Schall
    Chairman of the Board, President, Chief Executive Officer
  • Susan Kanaya
    Chief Financial and Administrative Officer, Executive Vice President, Secretary, Director
  • Tausif Butt
    Chief Operating Officer, Executive Vice President
  • Rita Jain
    Chief Medical Officer, Executive Vice President, Director
  • Markus Cappel
    Chief Business Officer, Treasurer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.